肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

中国临床肿瘤学会( CSCO) 分化型甲状腺癌诊疗指南2021

2021-12-30 中国临床肿瘤学会 肿瘤预防与治疗

胃肠胰神经内分泌肿瘤分化型甲状腺癌

为推动甲状腺癌临床处置的规范化,中国临床肿瘤学会甲状腺癌专家委员会充分遵循多学科协作和规范化诊疗原则,积极参考国内外高质量文献并结合我国实际国情,在前期编写并修订的《持续/ 复发/ 转移性分化型甲状腺

中文标题：

中国临床肿瘤学会( CSCO) 分化型甲状腺癌诊疗指南2021

发布机构：

中国临床肿瘤学会

发布日期：

2021-12-30

简要介绍：

为推动甲状腺癌临床处置的规范化,中国临床肿瘤学会甲状腺癌专家委员会充分遵循多学科协作和规范化诊疗原则,积极参考国内外高质量文献并结合我国实际国情,在前期编写并修订的《持续/ 复发/ 转移性分化型甲状腺癌诊疗指南》基础上做了适度外延,组织撰写了第一版专注于分化型甲状腺癌诊断和治疗的多学科指南。

相关资料下载：
[AttachmentFileName(sort=1, fileName=中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021.pdf)] GetToolGuiderByIdResponse(projectId=1, id=eee111c002331a7c, title=中国临床肿瘤学会( CSCO) 分化型甲状腺癌诊疗指南2021, enTitle=, guiderFrom=肿瘤预防与治疗, authorId=0, author=, summary=为推动甲状腺癌临床处置的规范化,中国临床肿瘤学会甲状腺癌专家委员会充分遵循多学科协作和规范化诊疗原则,积极参考国内外高质量文献并结合我国实际国情,在前期编写并修订的《持续/ 复发/ 转移性分化型甲状腺, cover=https://img.medsci.cn/2022121/1642741014674_5579292.png, journalId=0, articlesId=null, associationId=863, associationName=中国临床肿瘤学会, associationIntro=null, copyright=0, guiderPublishedTime=Thu Dec 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">为推动甲状腺癌临床处置的规范化,中国临床肿瘤学会甲状腺癌专家委员会充分遵循多学科协作和规范化诊疗原则,积极参考国内外高质量文献并结合我国实际国情,在前期编写并修订的《持续/ 复发/ 转移性分化型甲状腺癌诊疗指南》基础上做了适度外延,组织撰写了第一版专注于分化型甲状腺癌诊断和治疗的多学</span><span style="color: #373737;">科指南。</span></p>, tagList=[TagDto(tagId=1095, tagName=胃肠胰神经内分泌肿瘤), TagDto(tagId=7891, tagName=分化型甲状腺癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=73, categoryName=头颈外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6615, appHits=230, showAppHits=0, pcHits=1962, showPcHits=6379, likes=2, shares=35, comments=11, approvalStatus=1, publishedTime=Fri Jan 21 12:54:38 CST 2022, publishedTimeString=2021-12-30, pcVisible=1, appVisible=1, editorId=0, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Fri Jan 21 13:00:00 CST 2022, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 17:29:35 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021.pdf)])
中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021.pdf
下载请点击：
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2125504, encodeId=d67321255046d, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:23:18 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2112874, encodeId=00d421128e42c, content=非常实用，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55028524889, createdName=ms9000000440021158, createdTime=Fri Feb 03 13:22:17 CST 2023, time=2023-02-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2088982, encodeId=771820889820a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Mon Sep 19 09:46:12 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213791, encodeId=3d9f1213e917f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96036538530, createdName=ms2000001337853851, createdTime=Sun Apr 24 00:18:28 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198630, encodeId=934f119863054, content=非常感谢，非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a65341903, createdName=HYH135135, createdTime=Wed Mar 02 10:32:19 CST 2022, time=2022-03-02, status=1, ipAttribution=)]
    2023-04-12 1471d48dm72暂无昵称 来自安徽省

    非常实用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2125504, encodeId=d67321255046d, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:23:18 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2112874, encodeId=00d421128e42c, content=非常实用，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55028524889, createdName=ms9000000440021158, createdTime=Fri Feb 03 13:22:17 CST 2023, time=2023-02-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2088982, encodeId=771820889820a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Mon Sep 19 09:46:12 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213791, encodeId=3d9f1213e917f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96036538530, createdName=ms2000001337853851, createdTime=Sun Apr 24 00:18:28 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198630, encodeId=934f119863054, content=非常感谢，非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a65341903, createdName=HYH135135, createdTime=Wed Mar 02 10:32:19 CST 2022, time=2022-03-02, status=1, ipAttribution=)]
    2023-02-03 ms9000000440021158 来自广西

    非常实用，谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2125504, encodeId=d67321255046d, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:23:18 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2112874, encodeId=00d421128e42c, content=非常实用，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55028524889, createdName=ms9000000440021158, createdTime=Fri Feb 03 13:22:17 CST 2023, time=2023-02-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2088982, encodeId=771820889820a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Mon Sep 19 09:46:12 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213791, encodeId=3d9f1213e917f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96036538530, createdName=ms2000001337853851, createdTime=Sun Apr 24 00:18:28 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198630, encodeId=934f119863054, content=非常感谢，非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a65341903, createdName=HYH135135, createdTime=Wed Mar 02 10:32:19 CST 2022, time=2022-03-02, status=1, ipAttribution=)]
    2022-09-19 1471d48dm72暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2125504, encodeId=d67321255046d, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:23:18 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2112874, encodeId=00d421128e42c, content=非常实用，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55028524889, createdName=ms9000000440021158, createdTime=Fri Feb 03 13:22:17 CST 2023, time=2023-02-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2088982, encodeId=771820889820a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Mon Sep 19 09:46:12 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213791, encodeId=3d9f1213e917f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96036538530, createdName=ms2000001337853851, createdTime=Sun Apr 24 00:18:28 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198630, encodeId=934f119863054, content=非常感谢，非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a65341903, createdName=HYH135135, createdTime=Wed Mar 02 10:32:19 CST 2022, time=2022-03-02, status=1, ipAttribution=)]
    2022-04-24 ms2000001337853851

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2125504, encodeId=d67321255046d, content=非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Wed Apr 12 20:23:18 CST 2023, time=2023-04-12, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2112874, encodeId=00d421128e42c, content=非常实用，谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55028524889, createdName=ms9000000440021158, createdTime=Fri Feb 03 13:22:17 CST 2023, time=2023-02-03, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2088982, encodeId=771820889820a, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43ff5192496, createdName=1471d48dm72暂无昵称, createdTime=Mon Sep 19 09:46:12 CST 2022, time=2022-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1213791, encodeId=3d9f1213e917f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96036538530, createdName=ms2000001337853851, createdTime=Sun Apr 24 00:18:28 CST 2022, time=2022-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1198630, encodeId=934f119863054, content=非常感谢，非常实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5a65341903, createdName=HYH135135, createdTime=Wed Mar 02 10:32:19 CST 2022, time=2022-03-02, status=1, ipAttribution=)]
    2022-03-02 HYH135135

    非常感谢，非常实用

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2021 日本临床实践指南：胰腺导管腺癌腹膜播散的管理（概要）

日本肝胆胰腺外科学会(JSHBPS,Japanese Society of Hepato-Biliary-Pancreatic Surgery) · 2021-12-02

2021 JNETS临床实践指南：胃肠胰神经内分泌肿瘤的诊断、治疗和随访（概要）

日本神经内分泌肿瘤学会 · 2021-09-29

中国胃肠胰神经内分泌肿瘤病理诊断共识(2020版)

中华医学会病理学分会 · 2021-01-08

2020 ESMO临床实践指南：胃肠胰神经内分泌肿瘤的诊断，治疗和随访

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2020-04-03

肿瘤病理诊断规范胃肠胰神经内分泌肿瘤

中国肿瘤科相关专家小组（统称） · 2017-02-07

2016 中国胃肠胰神经内分泌肿瘤专家共识

CSCO 神经内分泌肿瘤专家委员会 · 2016-10-30